Barclays Maintains an 'Equalweight' on Pall Corp (PLL); Q2 Preview
Tweet
Share
E-mailGet Alerts PLL Hot Sheet
Price: $7.25 --0%
Rating Summary:
6 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Pall Corp (NYSE: PLL) price target of $59.00.
Analyst, Nandita Koshal, said, "Heading into Q2 results later this week, our estimates for the quarter are roughly in-line with the Street (sales $680M, EPS $0.74). Accelerated operational improvements should yield results over the coming quarters, and we are modestly above consensus for the full year (FY12 EPS of $3.26 vs. Street at $3.21). Sentiment on the name has improved substantially based on management change, and we believe investors will increasingly look for clarity on LT margin and mix trajectory, and execution timeline."
For an analyst ratings summary and ratings history on Pall Corp click here. For more ratings news on Pall Corp click here.
Shares of Pall Corp closed at $62.10 yesterday.
Analyst, Nandita Koshal, said, "Heading into Q2 results later this week, our estimates for the quarter are roughly in-line with the Street (sales $680M, EPS $0.74). Accelerated operational improvements should yield results over the coming quarters, and we are modestly above consensus for the full year (FY12 EPS of $3.26 vs. Street at $3.21). Sentiment on the name has improved substantially based on management change, and we believe investors will increasingly look for clarity on LT margin and mix trajectory, and execution timeline."
For an analyst ratings summary and ratings history on Pall Corp click here. For more ratings news on Pall Corp click here.
Shares of Pall Corp closed at $62.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
